Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

IBD in 2010

Optimizing treatment and minimizing adverse events

Nature Reviews Gastroenterology & Hepatology volume 8, pages 74–76 (2011)Cite this article

Subjects

The management of IBD remains a challenge, with the main issue being to combine therapeutic efficiency with minimal side effects and optimal quality of life. Efforts towards achieving this objective continued in 2010—we discuss some of the most relevant publications and their potential impact on daily practice in the future.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Plevy, S. et al. A phase I study of visilizumab, a humanised anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. Gastroenterology 133, 1414–1422 (2007).

    Article  CAS  Google Scholar 

  2. Baumgart, D. C. et al. Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis. Inflamm. Bowel Dis. 16, 620–629 (2010).

    Article  Google Scholar 

  3. Sandborn, W. J. et al. Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis. Gut 59, 1485–1492 (2010).

    Article  CAS  Google Scholar 

  4. Colombel, J. F. et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N. Engl. J. Med. 362, 1383–1395 (2010).

    Article  CAS  Google Scholar 

  5. Grainge, M. J., West, J. & Card, T. R. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 375, 657–663 (2010).

    Article  Google Scholar 

  6. White, R. H. The epidemiology of venous thromboembolism. Circulation 107 (Suppl. 1), I4–I8 (2003).

    PubMed  Google Scholar 

  7. Sokol, H. & Beaugerie, L. Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle. Gut 58, 1427–1436 (2009).

    Article  CAS  Google Scholar 

  8. Long, M. D. et al. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 8, 268–274 (2010).

    Article  Google Scholar 

  9. Cheent, K. et al. Case report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease. J. Crohns Colitis 4, 603–605 (2010).

    Article  Google Scholar 

  10. Mahadevan, U. et al. One year newborn outcomes among offspring of women with inflammatory bowel disease: the PIANO registry [abstract 764]. Gastroenterology 138 (Suppl. 1), S-106 (2010).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d'Hépato-Gastroentérologie, Center Hospitalier Jolimont-Lobbes, Rue Ferrer 159, 7100, Haine-Saint-Paul, Belgium

    Bénédicte De Vroey

  2. Clinique des Maladies de l'Appareil digestif et de la Nutrition, Center Hospitalier Universitaire de Lille, Hôpital Huriez, Rue Michel Polonovski, Lille, 59037

    Jean-Frédéric Colombel

Authors
  1. Bénédicte De Vroey
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jean-Frédéric Colombel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jean-Frédéric Colombel.

Ethics declarations

Competing interests

J. F. Colombel has acted as a consultant for and has received grant/research support from Centocor, MSD, PDL and Schering-Plough. He has also been on the Speaker's Bureau (honoraria) for Centocor, MSD and Schering-Plough. B. De Vroey declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

De Vroey, B., Colombel, JF. Optimizing treatment and minimizing adverse events. Nat Rev Gastroenterol Hepatol 8, 74–76 (2011). https://doi.org/10.1038/nrgastro.2010.218

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrgastro.2010.218

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing